Header Logo

Connection

Bronwen Lambson to HIV Infections

This is a "connection" page, showing publications Bronwen Lambson has written about HIV Infections.
Connection Strength

0,478
  1. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLoS Pathog. 2023 06; 19(6):e1011469.
    View in: PubMed
    Score: 0,061
  2. Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms. Sci Rep. 2022 10 01; 12(1):16473.
    View in: PubMed
    Score: 0,058
  3. Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathog. 2022 09; 18(9):e1010450.
    View in: PubMed
    Score: 0,058
  4. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Front Immunol. 2021; 12:733958.
    View in: PubMed
    Score: 0,054
  5. Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. Immunity. 2019 07 16; 51(1):141-154.e6.
    View in: PubMed
    Score: 0,046
  6. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Rep. 2018 12 11; 25(11):3123-3135.e6.
    View in: PubMed
    Score: 0,044
  7. Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J Immunol. 2015 May 01; 194(9):4371-8.
    View in: PubMed
    Score: 0,034
  8. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014 Aug 13; 16(2):215-226.
    View in: PubMed
    Score: 0,033
  9. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug; 85(15):7719-29.
    View in: PubMed
    Score: 0,026
  10. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009 Sep; 5(9):e1000598.
    View in: PubMed
    Score: 0,023
  11. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 2019 12; 15(12):e1008064.
    View in: PubMed
    Score: 0,012
  12. Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. J Virol. 2019 05 15; 93(10).
    View in: PubMed
    Score: 0,011
  13. South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on a4ß7 for replication. Retrovirology. 2015 Jun 24; 12:54.
    View in: PubMed
    Score: 0,009
  14. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.